Stephen M. McLean

Partner
Arsenal Capital Partners

Steve McLean was a founding member and has served as Chairman of the Board of the International Biomedical Research Alliance since 2005.

Mr. McLean is a Senior Partner of Arsenal Capital Partners. Arsenal is a private equity fund that manages approximately $8 billion of equity capital. Mr. McLean is the Chairman of Arsenal’s Healthcare Group which focuses on investments in companies that improve the efficacy of pharmaceutical and bio-tech research and development, hospital and provider operations. Prior to joining Arsenal, Mr. McLean was a life science investor who co-founded HIT and genomics companies such as CentriHealth, Agencourt Bioscience, and Agencourt Personal Genomics.

Previously, Mr. McLean was a founding partner of Merrill Lynch Capital Partners (and successor funds) which was a leader in the development of the leveraged buyout industry.

Mr. McLean graduated with a B.S. in Economics, summa cum laude, from the Wharton School of the University of Pennsylvania and received an M.B.A., with distinction, from the Wharton School of the University of Pennsylvania. He currently serves on the board of directors of Accumen, CellCarta, Certara, and WCG Clinical.

Mr. McLean and his wife reside in New Jersey and have three children and seven grandchildren.

Justin Lathia, Ph.D.

Alumni Director
Lerner Research Institute, Cleveland Clinic
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Case Comprehensive Cancer Center

Dr. Justin Lathia leads a translational cancer stem cell research laboratory and is Vice Chair and Professor in the Department of Cardiovascular & Metabolic Sciences at the Lerner Research Institute (LRI), part of the Cleveland Clinic, and also serves as the Director of Faculty Development for the LRI. Dr. Lathia is also the Scientific Director of the Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center at the Cleveland Clinic and the Melvin Burkhardt Endowed Chair in Neuro-Oncology Research. He is also the Reza Khatib MD Professor, Leader of the Brain Tumor Initiative, and Co-Leader of the Molecular Oncology Program at the Case Comprehensive Cancer Center. Dr. Lathia is a native of central Pennsylvania and received a B.S. and M.S. from Drexel University in Philadelphia, PA in 2003. While at Drexel, he developed targeted ultrasound contrast agents which preferentially bound to newly formed vessels in breast cancer models.

After graduation from Drexel, Dr. Lathia completed his Ph.D. as part of the NIH-Cambridge Graduate Partnership Program. His work focused on the role of cell adhesion molecules during the development of the nervous system. After completing his Ph.D. in 2008 he completed post-doctoral fellowships at Duke and the Cleveland Clinic where he focused on the role of cell adhesion in regulating cancer stem cells in brain tumors. In 2012, Dr. Lathia moved to the Department of Cardiovascular & Metabolic Sciences as an independent investigator and the work in his lab focuses on how the stem cell state is regulated in advanced cancers. Projects in the Lathia laboratory involve understanding how cancer stem cells interact with their surrounding microenvironment as well as one another with the goal of identifying unique pathways for therapeutic development and a recent focus on sex differences in glioblastoma. Work in the Lathia laboratory has resulted in Phase 1 clinical trial aimed at targeting myeloid-derived suppressor cells that interact with cancer stem cells to suppress the immune system in glioblastoma.

Dr. Lathia has co-authored over 210 publications and work in his lab is currently supported by multiple National Institutes of Health grants and foundation grants. Dr. Lathia also contributes as a peer reviewer to over 150 journals, serves on the editorial board for Cell Reports, Cancer Research, and Neuro-Oncology, and has served on multiple grant review panels for the National Institutes of Health and private foundations. He recently served as a co-editor for a cancer stem cell textbook.

Ralph A. Korpman, M.D.

Executive Vice President and Chief Scientific Officer, UnitedHealth Group
Professor, School of Medicine, Loma Linda University

Dr. Ralph A. Korpman is a recognized pioneer in the medical informatics field, beginning with his early work in introducing the concept of automating the clinical laboratory more than four decades ago. Dr. Korpman received his Bachelor’s and doctoral degrees in 1971 and 1974 from Loma Linda University, where he also completed residencies in anatomic pathology and laboratory medicine and a fellowship in clinical hematology. He took his graduate business studies at the Claremont Graduate School.

Dr. Korpman has been instrumental in defining each new generation of health information systems over the years, being among the first to introduce the concepts of point-of-care systems, integrated clinical systems, and physician portals. He continues to advance his vision of the ubiquitous use of technology in health care by serving in a number of pivotal health care IT roles, including his current role as Executive Vice President and Chief Scientific Officer of UnitedHealth Group where he continues the work of CentriHealth, a company specializing in the new area of Individual Health Records.

Before founding CentriHealth, Dr. Korpman served as President and CEO of a number of companies including Health Data Sciences Corporation, a company that he founded to pioneer Electronic Medical Records, and as Chief Scientist at Medaphis Corporation and Per-Se Technologies. Previously, Dr. Korpman founded Medical Data Corporation, a company that developed a variety of turnkey information systems for hospitals and U.S. government facilities throughout the country.

In addition to his corporate work in health care informatics, Dr. Korpman is full professor at Loma Linda University School of Medicine and a clinical professor in the University of Tennessee’s School of Medicine.
Dr. Korpman is the recipient of a number of awards, including Entrepreneur of the Year and Health Care Pioneer. He is the author of over 100 refereed articles and a book. He has testified extensively over the years for Congress and for Federal agencies and was a founder of both the ANSI HISB and ISO TC 215. He is also committed to civic and community affairs, serving on several college and not-for-profit foundation boards of directors.

Dr. Korpman joined the Alliance board in 2018.

Scott Koenig, M.D., Ph.D.

President and CEO
MacroGenics, Inc.

Dr. Scott Koenig joined the Alliance Board of Directors in 2014. He is a co-founder and President and CEO of MacroGenics (NASDAQ: MGNX), a biotechnology company developing immune-based medicines to treat patients with cancer, autoimmune disorders, and infectious diseases. Prior to joining MacroGenics in 2001, he served as Senior Vice President of Research at MedImmune where he participated in the selection and maturation of the product pipeline. From 1984 through 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID) where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS.

Dr. Koenig is the Chairman of the Board of Directors at Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotech company developing genetic therapies for inherited diseases and Chairman of the Board of the Children’s Research Institute at Children’s National Medical Center. He co-chairs the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research at the University of Maryland. He also serves as a member of the MacroGenics Board of Directors, the Board of Directors of Children’s National Medical Center, the Biotechnology Industry Organization (BIO) Board of Directors, the Scientific Management Review Board of the NIH, and the Cornell University Council.

Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston, where he was elected to Alpha Omega Alpha. He completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, and is Board certified in Internal Medicine and Allergy and Immunology. Scott and his wife, Robin, have been married for 35 years and have two children.

Alan Jones

Senior Managing Director
Intermediate Capital Group

Alan Jones has been a member of the Board of the International Biomedical Research Alliance since 2005. AJ is the Senior Managing Director at the Intermediate Capital Group. AJ was the Managing Director and Head of Global Private Equity for Morgan Stanley & Co. He is Chairman of Morgan Stanley’s Private Equity Investment Committee and President of the Board of Directors of Morgan Stanley Private Equity Asia III. He also serves as a member of the Investment Committees for Morgan Stanley Expansion Capital, Morgan Stanley Infrastructure Partners, and Morgan Stanley Credit Partners and as a member of the Merchant Banking Department Executive Committee and Risk Committee. He also has served as a member of the Senior Management Committee of Morgan Stanley Investment Management. He currently serves as a Director of Access Cash, Creative Circle, and Reach Out Healthcare America. He has previously served as a Director of McKechnie Aerospace, EmployBridge, and Zenith.

AJ is a member of the Council on Foreign Relations; a member of Harvard’s Committee on University Resources; Co-Chairman of the Harvard Parents’ Fund; Chief Fund Agent for the Harvard Business School Class of 1987; Reunion Co-Chairman for the Harvard College Class of 1983; a member of the Foreign Policy Program Leadership Committee at the Brookings Institution; a Director of the U.S. Board of Shakespeare’s Globe; and on the Board of Governors of the Franklin & Eleanor Roosevelt Institute.

AJ has also previously served as President of the Board of Trustees of The Brearley School and Chairman of the All Souls Emergency Relief Fund; a David Rockefeller Fellow (2003-2004); a Director of Communities in Schools; a Director of the Franklin & Eleanor Roosevelt Institute; a Director of Physicians for Human Rights; a Director of Musica Viva; a Director of the Shakespeare Society; a Director of the Heart and Soul Charitable Foundation; and a Director of the Everybody Wins Foundation.

AJ received his AB Magna Cum Laude in Biochemical Sciences in 1983 from Harvard College, where he was elected to Phi Beta Kappa. In 1987, he received an MBA with High Distinction from Harvard Business School, where he was a Baker Scholar. He resides in Manhattan with his wife and two daughters.